vs
Side-by-side financial comparison of ARCBEST CORP (ARCB) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $998.8M, roughly 1.5× ARCBEST CORP). Organon & Co. runs the higher net margin — 10.0% vs -0.1%, a 10.1% gap on every dollar of revenue. On growth, ARCBEST CORP posted the faster year-over-year revenue change (3.3% vs -3.5%). Over the past eight quarters, ARCBEST CORP's revenue compounded faster (-3.7% CAGR vs -4.7%).
ArcBest Corporation is a leading U.S.-based logistics and transportation solutions provider. It offers end-to-end supply chain services including less-than-truckload freight shipping, full truckload services, warehousing, expedited delivery, and customized logistics consulting, serving enterprise, small business, and government clients across North America and select global markets.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
ARCB vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $998.8M | $1.5B |
| Net Profit | $-1.0M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 0.3% | — |
| Net Margin | -0.1% | 10.0% |
| Revenue YoY | 3.3% | -3.5% |
| Net Profit YoY | -133.1% | 67.8% |
| EPS (diluted) | $-0.05 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $998.8M | $1.5B | ||
| Q4 25 | $972.7M | $1.5B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $967.1M | $1.5B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $1.1B | $1.6B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | $-1.0M | $146.0M | ||
| Q4 25 | $-8.1M | $-205.0M | ||
| Q3 25 | $39.3M | $160.0M | ||
| Q2 25 | $25.8M | $145.0M | ||
| Q1 25 | $3.1M | $87.0M | ||
| Q4 24 | $29.0M | $109.0M | ||
| Q3 24 | $100.3M | $359.0M | ||
| Q2 24 | $46.9M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | 0.3% | — | ||
| Q4 25 | -0.8% | -9.8% | ||
| Q3 25 | 5.2% | 15.2% | ||
| Q2 25 | 3.6% | 14.4% | ||
| Q1 25 | 0.7% | 6.7% | ||
| Q4 24 | 3.8% | 8.1% | ||
| Q3 24 | 12.7% | 13.1% | ||
| Q2 24 | 4.5% | 14.6% |
| Q1 26 | -0.1% | 10.0% | ||
| Q4 25 | -0.8% | -13.6% | ||
| Q3 25 | 3.7% | 10.0% | ||
| Q2 25 | 2.5% | 9.1% | ||
| Q1 25 | 0.3% | 5.8% | ||
| Q4 24 | 2.9% | 6.8% | ||
| Q3 24 | 9.4% | 22.7% | ||
| Q2 24 | 4.4% | 12.1% |
| Q1 26 | $-0.05 | $0.55 | ||
| Q4 25 | $-0.35 | $-0.78 | ||
| Q3 25 | $1.72 | $0.61 | ||
| Q2 25 | $1.12 | $0.56 | ||
| Q1 25 | $0.13 | $0.33 | ||
| Q4 24 | $1.21 | $0.42 | ||
| Q3 24 | $4.23 | $1.38 | ||
| Q2 24 | $1.96 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.4M | — |
| Total DebtLower is stronger | $223.7M | — |
| Stockholders' EquityBook value | $1.3B | — |
| Total Assets | $2.5B | — |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $86.4M | — | ||
| Q4 25 | $124.2M | $574.0M | ||
| Q3 25 | $132.6M | $672.0M | ||
| Q2 25 | $139.7M | $599.0M | ||
| Q1 25 | $98.7M | $547.0M | ||
| Q4 24 | $157.2M | $675.0M | ||
| Q3 24 | $191.1M | $763.0M | ||
| Q2 24 | $260.5M | $704.0M |
| Q1 26 | $223.7M | — | ||
| Q4 25 | — | $8.6B | ||
| Q3 25 | $214.1M | $8.8B | ||
| Q2 25 | $241.4M | $8.9B | ||
| Q1 25 | $214.2M | $9.0B | ||
| Q4 24 | $189.1M | $8.9B | ||
| Q3 24 | $180.5M | $8.7B | ||
| Q2 24 | $203.6M | $8.7B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $752.0M | ||
| Q3 25 | $1.3B | $906.0M | ||
| Q2 25 | $1.3B | $733.0M | ||
| Q1 25 | $1.3B | $542.0M | ||
| Q4 24 | $1.3B | $472.0M | ||
| Q3 24 | $1.3B | $493.0M | ||
| Q2 24 | $1.2B | $144.0M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $12.9B | ||
| Q3 25 | $2.5B | $13.6B | ||
| Q2 25 | $2.5B | $13.5B | ||
| Q1 25 | $2.4B | $13.2B | ||
| Q4 24 | $2.4B | $13.1B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $12.2B |
| Q1 26 | 0.17× | — | ||
| Q4 25 | — | 11.49× | ||
| Q3 25 | 0.16× | 9.74× | ||
| Q2 25 | 0.19× | 12.14× | ||
| Q1 25 | 0.17× | 16.52× | ||
| Q4 24 | 0.14× | 18.81× | ||
| Q3 24 | 0.14× | 17.75× | ||
| Q2 24 | 0.17× | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARCB
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
